The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Strides is the first Indian company to get approval for the product.
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
